Renal Insufficiency

  • Fadi G. Lakkis
  • Manuel Martinez-Maldonado


Regardless of the primary etiology of renal disease, the progressive decline in renal function eventually leads to uremia. In most patients with chronic renal insufficiency the signs and symptoms of uremia manifest when glomerular filtration rate (GFR) decreases to less than 15–20mL/min. When GFR reaches a level lower than 5 mL/min, end-stage renal disease sets in and replacement therapy in the form of dialysis or transplantation becomes unavoidable. This chapter focuses on the conservative management of patients with chronic renal insufficiency who do not yet require renal replacement therapy.


Chronic Renal Failure Renal Replacement Therapy Phosphate Binder Chronic Renal Insufficiency Chronic Renal Disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hebert LA, Bay WH: On the natural tendency to progressive loss of remaining kidney function in patients with impaired renal function. Med Clin North Am 74: 1011–1024, 1990.PubMedGoogle Scholar
  2. 2.
    Martinez-Maldonado M, Benabe JE, Cordova HR: Chronic clinical intrinsic renal failure. In: DW Seldin, G Giebisch, eds, The Kidney: Physiology and Pathophysiology, 2nd ed. Raven Press, New York, 1992.Google Scholar
  3. 3.
    Jacobson H: Chronic renal failure: pathophysiology. Lancet 338: 419–423, 1991.PubMedCrossRefGoogle Scholar
  4. 4.
    Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118: 129–138, 1993.PubMedCrossRefGoogle Scholar
  5. 5.
    Tolins JP, Raij L: Antihypertensive therapy and the progression of chronic renal disease. Are there renoprotective drugs? Semin Nephrol 11: 538–548, 1991.PubMedGoogle Scholar
  6. 6.
    Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375–380, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med 111: 503–516, 1989.PubMedCrossRefGoogle Scholar
  8. 8.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462, 1993.PubMedCrossRefGoogle Scholar
  9. 9.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in mormotensive type II diabetic patients. Ann Intern Med 118: 577–581, 1993.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaplan NM: Renal parenchymal hypertension. In: Clinical Hypertension, 5th ed. Williams and Wilkins, Baltimore, 1990.Google Scholar
  11. 11.
    Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, for the Modification of Diet in Renal Disease study group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877–884, 1994.PubMedCrossRefGoogle Scholar
  12. 12.
    Mitch WE: Dietary protein restriction in patients with chronic renal failure. Kidney Int 40: 326–341, 1991.PubMedCrossRefGoogle Scholar
  13. 13.
    Lau K: Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int 36: 918–937, 1989.PubMedCrossRefGoogle Scholar
  14. 14.
    Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384–394, 1990.PubMedCrossRefGoogle Scholar
  15. 15.
    Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL: Long-term beneficial effects of angiotensinconverting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240–248, 1992.PubMedGoogle Scholar
  16. 16.
    Grundy SM: Management of hyperlipidemia of kidney disease. Kidney Int 37: 847–853, 1990.PubMedCrossRefGoogle Scholar
  17. 17.
    Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O’Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 39: S41–48, 1991.Google Scholar
  18. 18.
    Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor ß or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92: 2597–2601, 1993.PubMedCrossRefGoogle Scholar
  19. 19.
    Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor ßl. Nature 346: 371–374, 1990.PubMedCrossRefGoogle Scholar
  20. 20.
    Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor ß protects against scarring in experimental kidney disease. Nature 360: 361–364, 1992.PubMedCrossRefGoogle Scholar
  21. 21.
    Tang WW, Feng L, Vannice JL, Wilson CB: Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 93: 273–279, 1994.PubMedCrossRefGoogle Scholar
  22. 22.
    Woo DDL, Miao SYP, Pelayo JC, Woolf AS: Taxol inhibits progression of congenital polycystic kidney disease. Nature 368: 750–753, 1994.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaloyanides GJ: Aminoglycoside nephrotoxicity. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney, vol 2, 5th ed. Little, Brown, Boston, 1993.Google Scholar
  24. 24.
    Levison ME: New dosing regimens for aminoglycoside antibiotics. Ann Intern Med 117: 693–694, 1992.PubMedCrossRefGoogle Scholar
  25. 25.
    Schlondorff D: Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 44: 643–653, 1993.PubMedCrossRefGoogle Scholar
  26. 26.
    Whelton A, Stout RL, Spilman PS, Klassen DK: Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 112: 568–576.Google Scholar
  27. 27.
    Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310: 563–572, 1984.PubMedCrossRefGoogle Scholar
  28. 28.
    Ten RM, Torres VE, Milliner DS, Schwab TR, Holley KE, Gleich GJ: Acute interstitial nephritis: immunologic and clinical aspects. Mayo Clin Proc 63: 921–930, 1988.PubMedCrossRefGoogle Scholar
  29. 29.
    Galpin JE, Shinaberger JH, Stanley TM, Blumenkrantz MJ, Bayer AS, Friedman GS, Montgomerie JZ, Guze LB, Coburn JW, Glassock RJ: Acute interstitial nephritis due to methicillin. Am J Med 65: 756–765, 1978.PubMedCrossRefGoogle Scholar
  30. 30.
    Bennet WM, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DC: Drug Prescribing in Renal Failure. Dosing Guidelines for Adults, 2nd ed. American College of Physicians, Philadelphia, 1991.Google Scholar
  31. 31.
    Berns AS: Nephrotoxicity of contrast media. Kidney Im 36: 730–740, 1989.CrossRefGoogle Scholar
  32. 32.
    Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, Bashore TM: Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 320: 149–153, 1989.PubMedCrossRefGoogle Scholar
  33. 33.
    Cigarroa RG, Lange RA, Williams RH, Hillis LD: Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 86: 649–652, 1989.PubMedCrossRefGoogle Scholar
  34. 34.
    Coburn JW, Agre KL: Renal thromboembolism, atheroembolism, and other acute diseases of the renal arteries. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney, vol 2, 5th ed. Little, Brown, Boston, 1993.Google Scholar
  35. 35.
    Hou SH, Grossman SD, Madias NE: Pregnancy in women with renal disease and moderate renal insufficiency. Am J Med 78: 185–194, 1985.PubMedCrossRefGoogle Scholar
  36. 36.
    Surian M, Imbasciati E, Cosci P, et al.: Glomerular disease and pregnancy. A study of 123 pregnancies in patients with primary and secondary glomerular diseases. Nephron 36: 10 1105, 1984.Google Scholar
  37. 37.
    Rose BD: Diuretics. Kidney Int 39: 336–352, 1991.PubMedCrossRefGoogle Scholar
  38. 38.
    Warnock DG: Uremic acidosis. Kidney Int 34: 278–287, 1988.PubMedCrossRefGoogle Scholar
  39. 39.
    Ypersele De Strihou CVY: Potassium homeostasis in renal failure. Kidney Int 11: 491–504, 1977.CrossRefGoogle Scholar
  40. 40.
    Delmez JA, Slatopolsky E: Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 72: 735–739, 1991.PubMedCrossRefGoogle Scholar
  41. 41.
    Malluche H, Faugere MC: Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 38: 193–211, 1990.PubMedCrossRefGoogle Scholar
  42. 42.
    De Fronzo RA, Tobin JD, Rowe JW, et al.: Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 62: 425–435, 1978.CrossRefGoogle Scholar
  43. 43.
    Kaptein EM, Quion-Verde H, Choolzian CJ, et al.: The thyroid in end-stage renal disease. Medicine (Baltimore) 67: 187197, 1988.Google Scholar
  44. 44.
    Schaefer F, Ritz E, Kokot F, Massry SG: Metabolic and endocrine dysfunctions in uremia. In: RW Schrier, CW Gottschalk, eds, Diseases of the Kidney, vol 3, 5th ed. Little, Brown, Boston, 1993.Google Scholar
  45. Paganini EP, Rothmann SA, Paul P, Meagher RC: Hematologic abnormalities. In: JT Daugirdas, TS Ing, eds, Handbook of Dialysis, 1st ed. Little, Brown, Boston, 1988.Google Scholar
  46. 46.
    Lundin AP: Recombinant erythropoietin and chronic renal failure. Hosp Pract 26 (4): 61–69, 1991.Google Scholar
  47. 47.
    Abels R: Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. Semin Nephrol 10 (Suppl 1): 20–25, 1990.PubMedGoogle Scholar
  48. 48.
    Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108–114, 1989.PubMedCrossRefGoogle Scholar
  49. 49.
    Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308: 8–12, 1983.PubMedCrossRefGoogle Scholar
  50. 50.
    Centers for Disease Control: General recommendations on immunization. Guidelines from the immunization practices advisory committee. Ann Intern Med 111: 133–142, 1989.CrossRefGoogle Scholar
  51. 51.
    Bolton CF, Baltzan MA, Baltzan RB: Effects of renal transplantation on uremic neuropathy. N Engl J Med 284: 1170, 1971.PubMedCrossRefGoogle Scholar
  52. 52.
    Burt RK, Gupta-Burt S, Suki WN, Barcenas CG, Ferguson JJ, Van Buren CT: Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med 111: 635–640, 1989.PubMedCrossRefGoogle Scholar
  53. 53.
    Balaskas EV, Oreopoulos DG: Uremic pruritus. Dial Transplant 21: 278–284, 1992.Google Scholar
  54. 54.
    Bay WH, Hebert LA: The living donor in kidney transplantation. Ann Intern Med 106: 719–727, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Fadi G. Lakkis
    • 1
  • Manuel Martinez-Maldonado
    • 2
  1. 1.Nephrology Division Department of Medicine, Atlanta Department of Veterans Affairs Medical CenterEmory University School of Medicine and The Medical and Research ServicesDecaturUSA
  2. 2.Medical Service, Atlanta Department of Veterans Affairs Medical CenterEmory University School of Medicine and The Medical and Research ServicesDecaturUSA

Personalised recommendations